Aeon Global Health, Operating Arm of Authentidate Holding Corp., Names David C. Goldberg as its new Chief Operating Officer
Authentidate Holding Corp.
- Friday, September 15, 2017
- GAINESVILLE, Ga
Gainesville GA, September 13, 2017: Authentidate Holding Corp.(OTCQB:ADAT),a growth oriented company focused on developing and providing clinically actionable medical information and telemedicine services, announced today that David C. Goldberg, a former executive of Enzo Biochem, Inc (NYSE: ENZ), has joined the Company as its new Chief Operating Officer. As COO, Mr. Goldberg will have overall responsibility for the Company’s operations on a worldwide basis.
Mr. Goldberg, 60, is a 35-year veteran of the life sciences and health care industries. He joins Aeon after recently completing an extended stint at Enzo where he held numerous executive and managerial positions across the company’s operations, including President and General Manager of its clinical laboratory and research products divisions, leading both during major transitions in their business strategies. He has extensive expertise across the range of life sciences corporate functions including operations, marketing and sales, compliance, investor relations, and strategic planning. Prior to joining Enzo, Mr. Goldberg held marketing and management positions with both NEN Life Sciences, (now Perkin Elmer (NYSE: PKI)) and Gallard Schlesinger Chemical Manufacturing (now Budenheim USA).
“All of us at Aeon Global Health are excited and enthusiastic about having David join our family,” said Sonny Roshan, Aeon’s Founder, Chairman and CEO. Over the past eighteen months, our team has worked tirelessly to lay the foundation needed to morph our Company into an emerging leader in medical informatics, while dealing with the ardent tasks that came with our reverse merger into Authentidate. I am proud to say that we have made substantial progress and are now beginning to execute on our plan. Bringing David to Aeon signals the formal launch of this initiative. His leadership skills, industry knowledge and track record of successes bode well for Aeon in both the short and long term”, he added.
“I am looking forward to my new role with the utmost of excitement”, said Mr. Goldberg. “The Aeon Global team is a dynamic, highly skilled group of professionals, backed by outstanding resources, including a 30,000-square foot state of the art building that has been built to the highest standards, a robust molecular-based research and development facility, and access to intellectual property in both the diagnostic and information technology spaces. We have already begun the process of vetting the myriad of opportunities that have been presented to Aeon, and as a result, expect to report on a number of developments and enhancements to the Company in the near term.”